Contact
searchSearch
HMP Global

Nonradiographic Axial Spondyloarthritis

Featured Article

News
Bimekizumab Demonstrates Rapid and Sustained Efficacy in Treating NrxSpA, Regardless of Prior TNF Inhibitor Exposure
12/21/2023
Hannah Musick
A new monoclonal antibody, bimekizumab (BKZ), demonstrated promising results in improving efficacy outcomes for patients with axial spondyloarthritis (axSpA), even in those who have lost response to TNF inhibitors or are intolerant to them,...
A new monoclonal antibody, bimekizumab (BKZ), demonstrated promising results in improving efficacy outcomes for patients with axial spondyloarthritis (axSpA), even in those who have lost response to TNF inhibitors or are intolerant to them,...
A new monoclonal antibody,...
12/21/2023
First Report Managed Care
News
NrxSpA Classification Holds Little Relevance in Daily Practice
11/06/2023
Jolynn Tumolo
While the terms nonradiographic axial spondyloarthritis (NrxSpA) and radiographic axial spondyloarthritis (R-axSpA) may sometimes be helpful for stratifying patients with axial spondyloarthritis (axSpA) in clinical studies, the terms are less...
While the terms nonradiographic axial spondyloarthritis (NrxSpA) and radiographic axial spondyloarthritis (R-axSpA) may sometimes be helpful for stratifying patients with axial spondyloarthritis (axSpA) in clinical studies, the terms are less...
While the terms nonradiographic...
11/06/2023
First Report Managed Care
News
Updated AS and NrxSpA Treatment Recommendations Identify Common Diagnosis Issues, Solutions
10/06/2023
Hannah Musick
Updated evidence-based recommendations were released for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, including the use of biologics and the role of imaging in patient management.
Updated evidence-based recommendations were released for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, including the use of biologics and the role of imaging in patient management.
Updated evidence-based...
10/06/2023
First Report Managed Care
News
Baseline MRI and CRP on Treatment Efficacy in NrxSpA
09/27/2023
Danielle Sposato
Over the past decade, biologics have made remarkable advancements in treating axial spondyloarthritis (axSpA). Despite these advances, many patients fail to attain full remission or inactive disease, with only approximately 60% achieving...
Over the past decade, biologics have made remarkable advancements in treating axial spondyloarthritis (axSpA). Despite these advances, many patients fail to attain full remission or inactive disease, with only approximately 60% achieving...
Over the past decade, biologics...
09/27/2023
First Report Managed Care
News
Upadacitinib Benefits Quality of Life and Work Productivity in Adults With NrAxSpA
08/29/2023
Jolynn Tumolo
Explore how Upadacitinib led to rapid and clinically meaningful gains in health-related quality of life and work productivity compared with placebo in patients with nonradiographic axial spondyloarthritis.
Explore how Upadacitinib led to rapid and clinically meaningful gains in health-related quality of life and work productivity compared with placebo in patients with nonradiographic axial spondyloarthritis.
Explore how Upadacitinib led to...
08/29/2023
First Report Managed Care
News
Unfamiliarity With NrAxSpa Can Delay Diagnosis for Years
07/27/2023
Jolynn Tumolo
“Education on cardinal features, epidemiology, burden, and benefits of timely NrAxSpa diagnosis is warranted for health care providers who commonly manage back pain,” researchers advised.
“Education on cardinal features, epidemiology, burden, and benefits of timely NrAxSpa diagnosis is warranted for health care providers who commonly manage back pain,” researchers advised.
“Education on cardinal features,...
07/27/2023
First Report Managed Care
News
Minimal Radiographic Progression Over 2 Years With Secukinumab for NrAxSpa
06/19/2023
Jolynn Tumolo
This study demonstrated minimal radiographic progression and sustained reduction in sacroiliac joint inflammation with secukinumab administered over 2 years for patients with NrAxSpa.
This study demonstrated minimal radiographic progression and sustained reduction in sacroiliac joint inflammation with secukinumab administered over 2 years for patients with NrAxSpa.
This study demonstrated minimal...
06/19/2023
First Report Managed Care
News
One-Fourth of Patients With NrAxSpa Experience No Disease Flare After Stopping Etanercept
05/23/2023
Jolynn Tumolo
Researchers investigate how the current differential diagnosis between radiographic and non-radiographic axial spondyloarthritis affects the prediction of patient outcomes.
Researchers investigate how the current differential diagnosis between radiographic and non-radiographic axial spondyloarthritis affects the prediction of patient outcomes.
Researchers investigate how the...
05/23/2023
First Report Managed Care
News
Continued Golimumab Superior to Withdrawal in Patients With Inactive NrAxSpa
04/21/2023
Jolynn Tumolo
Continued golimumab treatment was superior to withdrawal in preventing disease flares and achieving clinical responses in adults with inactive nonradiographic axial spondyloarthritis.
Continued golimumab treatment was superior to withdrawal in preventing disease flares and achieving clinical responses in adults with inactive nonradiographic axial spondyloarthritis.
Continued golimumab treatment...
04/21/2023
First Report Managed Care
News
Spinal Schwannoma Found in Man With Nonradiographic Axial Spondyloarthritis
03/09/2023
Jolynn Tumolo
A case study detailed the incidence of a rare tumor in a 25-year-old patient with a history of nonradiographic axial spondyloarthritis. 
A case study detailed the incidence of a rare tumor in a 25-year-old patient with a history of nonradiographic axial spondyloarthritis. 
A case study detailed the...
03/09/2023
First Report Managed Care
News
Earlier Treatment May Improve Outcomes in Patients With Nonradiographic Axial Spondyloarthritis
10/14/2022
Jolynn Tumolo
Study authors compared early vs late symptom duration and the efficacy of secukinumab in younger vs older patients with nonradiographic axial spondyloarthritis.
Study authors compared early vs late symptom duration and the efficacy of secukinumab in younger vs older patients with nonradiographic axial spondyloarthritis.
Study authors compared early vs...
10/14/2022
First Report Managed Care

Newsfeed

News
Bimekizumab Demonstrates Rapid and Sustained Efficacy in Treating NrxSpA, Regardless of Prior TNF Inhibitor Exposure
12/21/2023
Hannah Musick
A new monoclonal antibody, bimekizumab (BKZ), demonstrated promising results in improving efficacy outcomes for patients with axial spondyloarthritis (axSpA), even in those who have lost response to TNF inhibitors or are intolerant to them,...
A new monoclonal antibody, bimekizumab (BKZ), demonstrated promising results in improving efficacy outcomes for patients with axial spondyloarthritis (axSpA), even in those who have lost response to TNF inhibitors or are intolerant to them,...
A new monoclonal antibody,...
12/21/2023
First Report Managed Care
News
NrxSpA Classification Holds Little Relevance in Daily Practice
11/06/2023
Jolynn Tumolo
While the terms nonradiographic axial spondyloarthritis (NrxSpA) and radiographic axial spondyloarthritis (R-axSpA) may sometimes be helpful for stratifying patients with axial spondyloarthritis (axSpA) in clinical studies, the terms are less...
While the terms nonradiographic axial spondyloarthritis (NrxSpA) and radiographic axial spondyloarthritis (R-axSpA) may sometimes be helpful for stratifying patients with axial spondyloarthritis (axSpA) in clinical studies, the terms are less...
While the terms nonradiographic...
11/06/2023
First Report Managed Care
News
Updated AS and NrxSpA Treatment Recommendations Identify Common Diagnosis Issues, Solutions
10/06/2023
Hannah Musick
Updated evidence-based recommendations were released for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, including the use of biologics and the role of imaging in patient management.
Updated evidence-based recommendations were released for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, including the use of biologics and the role of imaging in patient management.
Updated evidence-based...
10/06/2023
First Report Managed Care
News
Baseline MRI and CRP on Treatment Efficacy in NrxSpA
09/27/2023
Danielle Sposato
Over the past decade, biologics have made remarkable advancements in treating axial spondyloarthritis (axSpA). Despite these advances, many patients fail to attain full remission or inactive disease, with only approximately 60% achieving...
Over the past decade, biologics have made remarkable advancements in treating axial spondyloarthritis (axSpA). Despite these advances, many patients fail to attain full remission or inactive disease, with only approximately 60% achieving...
Over the past decade, biologics...
09/27/2023
First Report Managed Care
News
Upadacitinib Benefits Quality of Life and Work Productivity in Adults With NrAxSpA
08/29/2023
Jolynn Tumolo
Explore how Upadacitinib led to rapid and clinically meaningful gains in health-related quality of life and work productivity compared with placebo in patients with nonradiographic axial spondyloarthritis.
Explore how Upadacitinib led to rapid and clinically meaningful gains in health-related quality of life and work productivity compared with placebo in patients with nonradiographic axial spondyloarthritis.
Explore how Upadacitinib led to...
08/29/2023
First Report Managed Care
News
Unfamiliarity With NrAxSpa Can Delay Diagnosis for Years
07/27/2023
Jolynn Tumolo
“Education on cardinal features, epidemiology, burden, and benefits of timely NrAxSpa diagnosis is warranted for health care providers who commonly manage back pain,” researchers advised.
“Education on cardinal features, epidemiology, burden, and benefits of timely NrAxSpa diagnosis is warranted for health care providers who commonly manage back pain,” researchers advised.
“Education on cardinal features,...
07/27/2023
First Report Managed Care
News
Minimal Radiographic Progression Over 2 Years With Secukinumab for NrAxSpa
06/19/2023
Jolynn Tumolo
This study demonstrated minimal radiographic progression and sustained reduction in sacroiliac joint inflammation with secukinumab administered over 2 years for patients with NrAxSpa.
This study demonstrated minimal radiographic progression and sustained reduction in sacroiliac joint inflammation with secukinumab administered over 2 years for patients with NrAxSpa.
This study demonstrated minimal...
06/19/2023
First Report Managed Care
News
One-Fourth of Patients With NrAxSpa Experience No Disease Flare After Stopping Etanercept
05/23/2023
Jolynn Tumolo
Researchers investigate how the current differential diagnosis between radiographic and non-radiographic axial spondyloarthritis affects the prediction of patient outcomes.
Researchers investigate how the current differential diagnosis between radiographic and non-radiographic axial spondyloarthritis affects the prediction of patient outcomes.
Researchers investigate how the...
05/23/2023
First Report Managed Care
News
Continued Golimumab Superior to Withdrawal in Patients With Inactive NrAxSpa
04/21/2023
Jolynn Tumolo
Continued golimumab treatment was superior to withdrawal in preventing disease flares and achieving clinical responses in adults with inactive nonradiographic axial spondyloarthritis.
Continued golimumab treatment was superior to withdrawal in preventing disease flares and achieving clinical responses in adults with inactive nonradiographic axial spondyloarthritis.
Continued golimumab treatment...
04/21/2023
First Report Managed Care
News
Spinal Schwannoma Found in Man With Nonradiographic Axial Spondyloarthritis
03/09/2023
Jolynn Tumolo
A case study detailed the incidence of a rare tumor in a 25-year-old patient with a history of nonradiographic axial spondyloarthritis. 
A case study detailed the incidence of a rare tumor in a 25-year-old patient with a history of nonradiographic axial spondyloarthritis. 
A case study detailed the...
03/09/2023
First Report Managed Care
News
Medicaid Coverage Remains Suboptimal After Medicare Enrollment
08/03/2026
Rebecca Amrick
A study found that waiving the Medicare Savings Program (MSP) asset test could help newly enrolled Medicare beneficiaries retain Medicaid coverage, but variations in state-level coverage and suboptimal rates of enrollment raise concerns about...
A study found that waiving the Medicare Savings Program (MSP) asset test could help newly enrolled Medicare beneficiaries retain Medicaid coverage, but variations in state-level coverage and suboptimal rates of enrollment raise concerns about...
A study found that waiving the...
08/03/2026
First Report Managed Care
Behind the Bill
Court Challenge Tests CMS' New Medicaid Work Requirement Rule
07/31/2026
Hannah Musick
A federal court has allowed CMS' new Medicaid work requirement rule to move forward while a multistate legal challenge continues, setting the stage for a broader debate over how the landmark eligibility changes will be implemented nationwide.
A federal court has allowed CMS' new Medicaid work requirement rule to move forward while a multistate legal challenge continues, setting the stage for a broader debate over how the landmark eligibility changes will be implemented nationwide.
A federal court has allowed CMS'...
07/31/2026
First Report Managed Care
News
GLP-1 RAs Have Higher Utilization Among Patients With Obesity Than Bariatric Surgery
07/28/2026
Rebecca Amrick
A study found that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are the more common treatment option for obesity among adolescents and young adults compared to bariatric surgery.
A study found that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are the more common treatment option for obesity among adolescents and young adults compared to bariatric surgery.
A study found that glucagon-like...
07/28/2026
First Report Managed Care
News
Kidney Transplant Referrals Show Significant Attrition Before Waitlisting
07/28/2026
Grace Taylor, MS, MA
A large US electronic health record analysis found that only 1 in 10 patients referred for kidney transplantation ultimately received a transplant, highlighting substantial attrition before waitlisting and identifying key patient- and...
A large US electronic health record analysis found that only 1 in 10 patients referred for kidney transplantation ultimately received a transplant, highlighting substantial attrition before waitlisting and identifying key patient- and...
A large US electronic health...
07/28/2026
First Report Managed Care
News
Insurance Coverage Impacts Episode of Care for Spinal Fusions
07/27/2026
Rebecca Amrick
A study found that among patients who underwent lumbar fusions, those covered by Medicare Advantage had longer lengths of stay and higher rates of home discharges than those covered by Medicare Fee-For-Service, illustrating gaps in episode of...
A study found that among patients who underwent lumbar fusions, those covered by Medicare Advantage had longer lengths of stay and higher rates of home discharges than those covered by Medicare Fee-For-Service, illustrating gaps in episode of...
A study found that among...
07/27/2026
First Report Managed Care
News
US Study Identifies Factors Linked to Low Metabolic Bariatric Surgery Uptake
07/24/2026
Grace Taylor, MS, MA
A large US cohort study found that only 3% of adults newly diagnosed with obesity underwent metabolic bariatric surgery within one year, with provider type, body mass index, sex, and other clinical factors strongly influencing access to...
A large US cohort study found that only 3% of adults newly diagnosed with obesity underwent metabolic bariatric surgery within one year, with provider type, body mass index, sex, and other clinical factors strongly influencing access to...
A large US cohort study found...
07/24/2026
First Report Managed Care
Behind the Bill
Federal Court Pauses Key ACA Marketplace Rule Changes
07/23/2026
Hannah Musick
A federal court has temporarily blocked several key provisions of Centers for Medicare & Medicaid Services' (CMS') 2027 Affordable Care Act (ACA) Marketplace rule, setting up a high-stakes legal battle over federal authority, Marketplace...
A federal court has temporarily blocked several key provisions of Centers for Medicare & Medicaid Services' (CMS') 2027 Affordable Care Act (ACA) Marketplace rule, setting up a high-stakes legal battle over federal authority, Marketplace...
A federal court has temporarily...
07/23/2026
First Report Managed Care
News
CMS Proposes New Medicaid Provider Tax Thresholds Under WFTC Legislation
07/23/2026
Grace Taylor, MS, MA
The Centers for Medicare & Medicaid Services (CMS) has proposed sweeping changes to Medicaid provider tax regulations that would establish new indirect hold harmless thresholds, expand reporting requirements, and reshape state health...
The Centers for Medicare & Medicaid Services (CMS) has proposed sweeping changes to Medicaid provider tax regulations that would establish new indirect hold harmless thresholds, expand reporting requirements, and reshape state health...
The Centers for Medicare &...
07/23/2026
First Report Managed Care
News
Fabhalta (Iptacopan) Receives FDA Approval to Slow Disease Progression in Patients With IgAN
07/22/2026
Rebecca Amrick
The US Food and Drug Administration (FDA) recently approved Fabhalta (iptacopan) to slow kidney function decline in patients with immunoglobulin A nephropathy (IgAN).
The US Food and Drug Administration (FDA) recently approved Fabhalta (iptacopan) to slow kidney function decline in patients with immunoglobulin A nephropathy (IgAN).
The US Food and Drug...
07/22/2026
First Report Managed Care
News
Obesity Subphenotype With Low GLP-1 Levels Shows Greater Weight Loss With Tirzepatide
07/21/2026
Hannah Musick
Researchers identified an obesity subphenotype characterized by rapid gastric emptying and low endogenous GLP-1 production that achieved nearly twice the weight loss with tirzepatide as other obesity phenotypes, highlighting the potential for...
Researchers identified an obesity subphenotype characterized by rapid gastric emptying and low endogenous GLP-1 production that achieved nearly twice the weight loss with tirzepatide as other obesity phenotypes, highlighting the potential for...
Researchers identified an...
07/21/2026
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use